Enterococcus faecalis as Next Generation Probiotics
As one of the current most popular therapies, next-generation probiotics (NGPs) are effective at disease prevention and treatment. Creative Biolabs provides a series of Enterococcus faecalis (E. faecalis)-based drug discovery and development services for our clients all over the world. Equipped with a team of professional scientists, we are capable of providing you with a wide spectrum of customized services on E. faecalis studies. We can accommodate the specific properties of your project and provide flexible integrated solutions.
Introduction to E. faecalis
E. faecalis is a gram-positive bacterium that is responsible for many infectious diseases in humans, such as human urinary tract infections. E. faecalis can be found in most parts of the human body, especially in the gastrointestinal tract, vagina, and intestines. Normally, E. faecalis is a friendly commensal bacterium in the intestines, but it can lead to serious human diseases if it spreads to other human tissues.
Currently, a wide variety of E. faecalis strains or species, like OG1SSp (pAM714), NCTC 12697, and v583, have been isolated and identified in different human samples. Infections with E. faecalis can show many symptoms, including but not limited to fever, headache, diarrhea, vomiting, as well as stiff neck, based on specific E. faecalis types. Moreover, pilot studies have demonstrated that the treatment for E. faecalis-based infection diseases can be particularly difficult due to their resistance to many types of antibiotics. In recent years, many reports have revealed that E. faecalis can be used as NGP candidates for preventing or treating certain human and animal diseases.
Fig.1 Histological analysis of E. faecalis cultured in the blood agar medium. (Callegan, 1999)
E. faecalis for Disease Treatment
E. faecalis has been considered as the main type of live biotherapeutics drug in a wide collection of disease therapy. In recent years, a number of E. faecalis-based NGPs have also been generated and used both in pre-clinical trials and clinical trials. As an expert in NGP development, Creative Biolabs has established a panel of assays to develop various types of E. faecalis-based NGPs for human disease therapies.
Parkinson's disease is a type of neurodegenerative disorder that is often caused by the loss of dopaminergic neurons. Symptoms emerge slowly, sometimes beginning with shaking, stiffness, and slowing of movement. Till now, many researchers have indicated that several E. faecalis strains have beneficial health effects in treating patients with Parkinson's disease. For example, the safety and efficacy of E. faecalis strain v583 have been evaluated in 50 patients with Parkinson's disease and 50 healthy controls. The data have suggested that E. faecalis-based NGPs play an important role in reducing pro-inflammatory cytokines and inhibiting the overgrowth of pathogenic bacteria in patients.
Inflammatory bowel disease (IBD) is an intestinal disorder that can cause chronic inflammation of the digestive tract and the gut. Recently, some E. faecalis strains have been reported as perfect NGP candidates for the IBD treatment through mediating the immune responses. There is a wealth of evidence that E. faecalis can inhibit the development and progression of IBD by regulating immune systems. For instance, the protective role of inactivated E. faecalis strain EF-2001 has been assessed on female NC/Nga mice models. EF-2001 can effectively prevent colonic tissue destruction in mice with IBD.
With the commitment of being your best NGP discovery partner, Creative Biolabs has established the utmost efficient integrated solutions to innovate and accelerate your E. faecalis-based NGP development for various types of diseases. We have won a good reputation among our worldwide customers for accomplishing numerous challenging projects on E. faecalis NGPs. We have experienced experts and advanced platforms that can provide excellent services. If you are interested in our services, please contact us to get more information and a quote for your project details.
Reference
-
Callegan, M., et al. Pathogenesis and Immunology of Bacterial Endophthalmitis. Infection and Immunity. 1999, 67(7): 3348-56.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
